Open access
Sep 2026
Protective effects of trimetazidine against pembrolizumab-induced cardiac injury: biochemical and immunohistochemical evaluation
Pembrolizumab, an immune checkpoint inhibitor targeting programmed cell death protein-1 (PD-1), has substantially improved cancer treatment outcomes but may induce immune-related cardiotoxicity characterized by oxidative stress, inflammation, and apoptosis. Trimetazidine is a metabolic modulator with antioxidant and...
Ozlem Admis, Esra Tuba Sezgin, M. Ozkaraca et al.
· Scientific Reports · 0 citations